Soluble c-erbB-2 Oncoprotein Levels in Renal Cell Carcinoma
Author Information
Author(s): T Rasmuson, K Grankvist, B Ljungberg
Primary Institution: UmeA University
Hypothesis
The study aims to evaluate the serum levels of the soluble ectodomain of c-erbB-2 oncoprotein in renal cell carcinoma in relation to clinicopathological parameters and the clinical course of disease.
Conclusion
The study found an inverse relationship between serum levels of the soluble ectodomain of c-erbB-2 oncoprotein and disease stage, tumor grade, and survival time in renal cell carcinoma.
Supporting Evidence
- The median serum level of c-erbB-2 ectodomain was 2062 U/ml.
- Survival time for patients with serum levels above the median was significantly longer than for those with lower levels.
- An inverse relation between disease stage and serum level of c-erbB-2 ectodomain was observed.
Takeaway
Doctors looked at a protein in the blood of kidney cancer patients to see if it could help predict how serious their cancer was. They found that lower levels of this protein meant worse cancer.
Methodology
Serum levels of c-erbB-2 oncoprotein were measured using a sandwich enzyme immunoassay in sera from 184 patients with renal cell carcinoma before treatment.
Limitations
The study may have limitations related to the sample size and the specific population studied, which may not be generalizable.
Participant Demographics
112 male and 72 female patients with a median age of 66 years (range 25-85 years).
Statistical Information
P-Value
0.0017
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website